As per the recent market research conducted by FMI, the global metagenomics market is expected to advance at a CAGR of 6.9% during the forecast period. The valuation in 2023 is expected to be USD 202.9 million. By 2033, the market value is expected to be USD 394.2 million.
Key factors that may propel the market growth are:
The COVID-19 pandemic is likely to redirect attention to the growing metagenomics business.
As per an article in Future Science, 2021, pandemic risk calculations use metagenomics to trace the molecular changes in pathogens during their emergence. This could aid in the prediction of hotspots of emergence, populations at risk, and pathogens undergoing genetic evolution. Given the foregoing, the COVID-19 pandemic is projected to have a substantial influence on the metagenomics analysis.
Collaborations between government and business entities are also expected to generate sales opportunities for metagenomics throughout the projected period. For example, in October 2021, the USA Food and Drug Administration, the National Institute of Health, and 15 commercial groups entered a strategic partnership. The idea was to discover gene therapy for 30 million Americans who suffer from uncommon diseases.
Key developments in the market include the advancement of sequencing technologies from shotgun sequencing to high-throughput, next-generation sequencing, and third-generation sequencing. These developments would provide an impetus for favorable growth opportunities for market players in the coming years.
As per the regional analysis, North America is expected to be the dominant market. The market will be driven by increased demand for metagenomic sequencing due to the existence of biotechnological firms, and the rising incidence of chronic illnesses. An increase in the number of human genome research initiatives and the adoption of improved diagnostic procedures are also expected to drive market growth.
| Attributes | Value |
|---|---|
| Metagenomics Market Value (2022) | USD 189.2 million |
| Metagenomics Market Expected Value (2023) | USD 202.9 million |
| Metagenomics Market Forecast Value (2033) | USD 394.2 million |
| Metagenomics Market Expected CAGR (2023 to 2033) | 6.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Metagenomics has been in demand owing to its ability to study every type of microorganism, regardless of whether it can be cultured or not. The ability to study prokaryotes and viruses in the environment through the analysis of their DNA makes metagenomics a powerful method. The capability to identify crucial bioactive compounds, enzymes, and antibiotics make metagenomics a highly reliable method. Owing to its increased usage the anticipated CAGR is expected to be more than the historical CAGR. The historical CAGR for the market was 6.4% and the anticipated CAGR is 6.9%.
As the global burden of chronic diseases continues to rise, research is conducted to test the potentiality of metagenomics for timely diagnosis. This is anticipated to bolster the growth in the metagenomics market.
Metagenomic diagnostics help predict and manage the treatment of a plethora of diseases. It can be effectively used to discover hidden genetic features that could prove vital in various usages. Key applications are in novel enzymes, bioactive molecules, and genes with better or new biochemical functionalities.
In addition, the growing adoption of diagnostic tests based on metagenomics for the early diagnosis of genetic disorders will further expand the market.
Principal Consultant
Metagenomics plays a crucial role in bioremediation, a process that uses naturally occurring or artificially introduced microorganisms to break down environmental pollutants.
Metagenomic approaches reveal useful information about the metagenome of microorganisms, which play a key role in the biogeochemical cycles. These are also used for the detoxification of environmental pollutants using culture-independent molecular techniques.
Targeted metagenomics is used to study the phylogenetic diversity and relative abundance of a particular gene in the environment. The increasing need for preventing and controlling environmental toxicity through bioremediation will therefore create growth opportunities for the market.
| Regions | North America |
|---|---|
| Country | United States of America |
| CAGR (2023 to 2033) | 8% |
| Region | Europe |
|---|---|
| Country | United Kingdom |
| CAGR (2023 to 2033) | 5.8% |
| Region | Asia Pacific |
|---|---|
| Country | China |
| CAGR (2023 to 2033) | 8.6% |
| Region | Asia Pacific |
|---|---|
| Country | Japan |
| CAGR (2023 to 2033) | 5.3% |
| Region | Asia Pacific |
|---|---|
| Country | India |
| CAGR (2023 to 2033) | 6.8% |
Rising prevalence of chronic diseases fueling the adoption of metagenomic sequencing
The USA is projected to dominate the North American market over the forecast period. Increasing demand for metagenomic sequencing due to the heavy presence of biotechnological companies and the rising prevalence of chronic diseases are expected to drive the market. A surge in the number of human genome research projects and the adoption of better diagnostic techniques might as well propel growth.
| Attributes | Details |
|---|---|
| United States of America Market Expected Size (2033) | USD 110.3 million |
| United States of America Market Absolute Dollar Growth | USD 59.4 million |
| CAGR % 2017 to 2022 | 6.2% |
The USA is home to some of the leading pharmaceutical and biotech companies in the world. These companies are constantly employing techniques such as metagenomic sequencing for studying the nature and pattern of diseases as well as for developing targeted medicines.
The heavy presence of end-use industries generates demand for metagenomic approaches like shotgun sequencing in the United Kingdom
The United Kingdom market is slated to grow at a robust pace over the forecast period, owing to the presence of leading end-use industries, and the growing popularity of shotgun sequencing. The high prevalence of genetic disorders and the continuous rise in genetic research projects are also expected to surge the growth.
| Attributes | Details |
|---|---|
| United Kingdom Market Expected Size (2033) | USD 11.1 million |
| United Kingdom Market Absolute Dollar Growth | USD 4.8 million |
| CAGR % 2017 to 2022 | 8.8% |
Increasing efforts by the government and private organizations to make the United Kingdom an advanced genomic healthcare system market. The country is one of the leading players in genetics and genome sequencing and spends billions of dollars on developing new diagnostic tools and drugs for a wide range of diseases.
Increasing investments in gene research triggering growth in China
As per FMI, China is anticipated to lead the metagenomics market across the Asia Pacific excluding the Japan region throughout the forecast period. Growth in the market is driven by increasing demand for genetic sequencing, the prevalence of infectious diseases, and increasing investments in gene research.
| Attributes | Details |
|---|---|
| China Market Expected Size (2033) | USD 40.2 million |
| China Market Absolute Dollar Growth | USD 22.5 million |
| CAGR % 2017 to 2022 | 7.3% |
Rising investments in the healthcare sector by the government and other organizations are expected to fuel the growth in the market. For instance, in 2017 China launched the world’s largest human genome research project of 100,000 people to document their genetic makeup.
The growing popularity of metagenomics-based advanced gene sequencing techniques across agricultural and pharmaceutical industries is positively impacting growth.
The Japanese market is mainly driven by a number of endangered species, some of which are the Asian leopard cat, Blakiston’s fish-owl, brown spotted catshark, etc. The zoologists and wildlife veterinarians in Japan are laying a lot of emphasis on their protection.
Metagenomics plays a key role in their conservation. The DNA sequencing technology of metagenomics allows for the identification of microbiomes among and within the hosts. Incorporating the microbial host and biogeographic variation assists in the forest corridor assessments, which helps in gaining a proper understanding of microbial pathogens. Adoption of these methods would help in protecting endangered species.
| Attributes | Details |
|---|---|
| Japan Market Expected Size (2033) | USD 24.9 million |
| Japan Market Absolute Dollar Growth | USD 10 million |
| CAGR % 2017 to 2022 | 5.8% |
India is home to numerous diabetic patients in the world. Based on a survey conducted in December 2022, there are more than 74 million adults who suffer from diabetes. This is to say that 1 in 6 adults suffer from diabetes.
| Attributes | Details |
|---|---|
| India Market Expected Size (2033) | USD 20.9 million |
| India Market Absolute Dollar Growth | USD 10.1 million |
| CAGR % 2017 to 2022 | 7.4% |
The metagenomic shotgun sequencing and metabolomic profiling identify specific human gut microbiota associated with diabetic retinopathy in type 2 diabetes. Healthcare has recently suggested a functional model for the development of autoimmunity for type 1 diabetes. These developments are expected to surge the demand for metagenomics in India.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Segment | Product Type |
|---|---|
| Attributes | Library Preparation Kits |
| CAGR % 2017 to 2022 | 6.3% |
| CAGR % 2023 to 2033 | 7.2% |
| Segment | Application |
|---|---|
| Attributes | Clinical Diagnostics |
| CAGR % 2017 to 2022 | 6.8% |
| CAGR % 2023 to 2033 | 8.3% |
Sales of library preparation kits to rise at robust pa ace as gene sequencing gains centerstage
As per FMI, sales in the library preparation kits segment accounted for a share of 42.0% in 2022.
DNA and RNA sequencing practices are gaining traction owing to their ability to provide valuable data about gene sequences in a small duration of time. The data generated through gene sequencing is then analyzed and used by clinicians, scientists, and researchers across various verticals such as agriculture, forensics, etc.
Library preparation kits provide efficient and quick extraction of gene segments which are then used for analysis. Moreover, advancements in technology are encouraging manufacturers to launch novel products that reduce error and stress while improving accuracy.
Clinical diagnostics to remain a key application area for metagenomics
By application, demand in the clinical diagnostics and bioremediation segments is expected to remain high over the forecast period. During the last few decades, metagenomics has gained immense traction across the healthcare industry where it is being utilized for diagnostic procedures.
Similarly, metagenomics procedures are being adopted for reducing toxicity in the environment. The rising usage of metagenomics in clinical diagnostics and bioremediation is anticipated to boost the growth in the market during the forecast period.
Demand for metagenomics remains high in pharmaceutical industries and academic and research Institutes
In terms of end use, pharmaceutical, and academic & research segments are likely to generate the maximum revenue through 2033.
With the rising prevalence of multiple chronic diseases, pharmaceutical companies and government health organizations are investing in the development of innovative drugs. Thus, the application of metagenomics is expected to increase over the forecast period. Similarly, various research activities are being conducted across educational institutions for studying and elucidating the genetic structure of microbial communities.
The start-ups have developed metagenomic screening tools to aid bio-discovery. The platform developed by them enables the expression of genes from diverse sources. The combination of automation, computation, and high-throughput screening assists in capturing a large variety of proteins.
Metagenomi: The start-up utilizes metagenomics to discover next-generation gene-editing tools. The discovery engine developed by Metagenomi uses AI-backed cloud computing to find natural enzyme systems in microbial environments. It finds compact nucleases that enable the delivery of AAV vectors. The search solution developed by them is mainly for therapeutic solutions. In January 2023, Metagenomi closed oversubscribed Series B funding standing at USD 275 million to lead therapeutic programs into clinical development.
The key players look to form profitable strategic collaborations. This would enable them to develop a combined framework of technologies that can increase the yield and find promising drugs based on human omics insights. In October 2022, Illumina launched a strategic collaboration with AstraZeneca for accelerating drug target discovery.
Key developments in the market are:
Dominant players in the market are:
| Company | Illumina |
|---|---|
| Description | Illumina has always worked towards improving human health by unlocking the power of the genome. By delivering breakthroughs in genomics, the company empowers visionaries around the globe to uncover answers. The company has enabled researchers and clinicians to turn big dreams into impactful genomic discoveries that improve lives. Inspired by deep customer insights, Illumina leads the way in delivering purposeful advances that address critical needs and enable support researchers. |
| Company | PerkinElmer |
|---|---|
| Description | PerkinElmer is a global provider of end-to-end solutions which help scientists, researchers, and clinicians better diagnose disease. With more than an 8-decade legacy of advancing science, the team of more than 16,000 collaborates with healthcare, academic, commercial, and government customers. The company reported revenues of more than USD 5 billion in 2021 and is currently serving in more than 190 countries. It is a component of the prestigious S&P 500 index. |
| Company | Trivitron Healthcare Pvt. Ltd. |
|---|---|
| Description | Being a part of this niche for more than two and a half decades, the journey of Trivitron as a medical technology presents a fascinating thread of inspiration. The company has been marketing its products to hospitals, healthcare providers, independent clinics, and laboratories. As a pioneer in this field, the company constantly pursues technological innovation to offer superior benefits at a lower cost. The company believes in delivering quality healthcare as a fundamental right. |
Other prominent companies profiled: are Qiagen N.V., and Thermo Fisher Scientific.
The market is valued at USD 202.9 million in 2023.
The top 3 companies leading in the market are Illumina, Thermo Fisher Scientific, and QIAGEN.
The life sciences industry is the primary consumer of the metagenomics market.
The market is estimated to reach USD 394.2 million by 2033.
The metagenomics market is expected to expand at a CAGR of 6.9% by 2033.
1. Executive Summary | Metagenomics Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product Type 5.1. Library Preparation Kits 5.2. Sample Extraction Kits 5.3. Sequencing Kits 6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application 6.1. Microbial Diversity 6.2. Bioremediation and Degradation 6.3. Bio Surfactants and Antibiotics Production 6.4. Clinical Diagnostics 6.5. Others 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 7.1. Pharmaceutical Industries 7.2. Research Laboratories 7.3. Biotechnology Companies 7.4. Pathology Laboratories 7.5. Academic and Research Institutes 7.6. Others 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. CIS & Russia 8.5. Asia-Pacific excluding Japan (APEJ) 8.6. Japan 8.7. Middle East and Africa (MEA) 9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 12. CIS & Russia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 13. APEJ Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 14. Japan Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 15. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Illumina Inc 18.2. Perkin Elmer Inc. 18.3. Trivitron Healthcare Pvt. Ltd. 18.4. Qiagen N.V. 18.5. Thermo Fisher Scientific 18.6. Symbio Scientific Pvt. Ltd. 18.7. Infobio 18.8. Bio-Rad Laboratories 18.9. Merck KgaA 18.10. Promega Corporation 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Metagenomics Market
